» Articles » PMID: 39605791

(+)-Borneol Inhibits Neuroinflammation and M1 Phenotype Polarization of Microglia in Epileptogenesis Through the TLR4-NFκB Signaling Pathway

Overview
Journal Front Neurosci
Date 2024 Nov 28
PMID 39605791
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the effect of (+)-borneol on neuroinflammation and microglia phenotype polarization in epileptogenesis and its possible mechanism.

Methods: Based on mouse models of status epilepticus (SE) induced by pilocarpine, and treated with 15 mg/kg (+)-borneol, western-blot was used to detect the expressions of NeuN, Iba-1, TLR4, p65 and p-p65 in the hippocampus. Immunofluorescence was used to detect the expression of apoptosis-related proteins Bax and Bcl-2. To explore the effect of (+)-borneol on microglia , we used the kainic acid-induced microglia model and the concentration of (+)-borneol was 25 μM according to CCK-8 results. The levels of tumor necrosis factor- (TNF-α), interleukin-1β (IL-1β) and interleukin-10 (IL-10) in the supernatant of each group was detected by ELISA. The nitric oxide (NO) content in the supernatant was detected by Griess method. The expressions of Iba-1 and TLR4-NFκB signaling pathway-related proteins (TLR4, p65, p-p65) were detected by Western-Blot. Immunofluorescence was used to detect microglia's M1 and M2 phenotype polarization and the expression of Iba-1 and TLR4.

Results: (+)-borneol reduced hippocampal neuronal injury, apoptosis, and microglia activation by inhibiting the TLR-NFκB signaling pathway in SE mice. TLR4 agonist LPS partially reversed the neuroprotective effect of (+)-borneol. In the KA-induced microglia model, (+)-borneol inhibited microglia activation, M1 phenotype polarization, and secretion of pro-inflammatory cytokines through the TLR4-NFκB signaling pathway. LPS treatment inhibited the therapeutic effects of (+)-borneol.

Conclusion: (+)-borneol inhibits microglial neuroinflammation and M1 phenotype polarization through TLR4-NFκB signaling pathway and reduces neuronal damage and apoptosis in SE mice. Therefore, (+)-borneol may be a potential drug for epilepsy modification therapy.

References
1.
Pracucci E, Pillai V, Lamers D, Parra R, Landi S . Neuroinflammation: A Signature or a Cause of Epilepsy?. Int J Mol Sci. 2021; 22(13). PMC: 8267969. DOI: 10.3390/ijms22136981. View

2.
Zou L, Zhang Y, Li W, Zhang J, Wang D, Fu J . Comparison of Chemical Profiles, Anti-Inflammatory Activity, and UPLC-Q-TOF/MS-Based Metabolomics in Endotoxic Fever Rats between Synthetic Borneol and Natural Borneol. Molecules. 2017; 22(9). PMC: 6151575. DOI: 10.3390/molecules22091446. View

3.
Thompson K . Status epilepticus and early development: Neuronal injury, neurodegeneration, and their consequences. Epilepsia Open. 2022; 8 Suppl 1:S110-S116. PMC: 10173843. DOI: 10.1002/epi4.12601. View

4.
Patel D, Tewari B, Chaunsali L, Sontheimer H . Neuron-glia interactions in the pathophysiology of epilepsy. Nat Rev Neurosci. 2019; 20(5):282-297. PMC: 8558781. DOI: 10.1038/s41583-019-0126-4. View

5.
Zhong Y, Qi Y, Jiang Z, Hu Y, Zhang X, Wu C . Analysis of medication rules and application characteristics of Chinese patent medicine containing borneol based on data mining. Heliyon. 2023; 9(11):e21232. PMC: 10641158. DOI: 10.1016/j.heliyon.2023.e21232. View